Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
Background This study aimed to evaluate the patient survival rates based on the use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in a large cohort of patients undergoing maintenance hemodialysis (HD).Methods Data from a national HD quality assessment pro...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2313173 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591082000482304 |
|---|---|
| author | Seok Hui Kang Gui Ok Kim Bo Yeon Kim Eun Jung Son Jun Young Do |
| author_facet | Seok Hui Kang Gui Ok Kim Bo Yeon Kim Eun Jung Son Jun Young Do |
| author_sort | Seok Hui Kang |
| collection | DOAJ |
| description | Background This study aimed to evaluate the patient survival rates based on the use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in a large cohort of patients undergoing maintenance hemodialysis (HD).Methods Data from a national HD quality assessment program were used in this retrospective study. The patients were classified into four groups based on the use of renin-angiotensin system blockers (RASBs) as follows: No group, patients without a prescription of any anti-hypertensive drugs including RASBs; Other group, patients with a prescription of anti-hypertensive drugs excluding RASBs; ACEI group, patients with a prescription of an ACEI; and ARB group, patients with a prescription of an ARB.Results The 5-year survival rates in the no, other, ACEI, and ARB groups were 68.6%, 67.8%, 70.6%, and 69.2%, respectively. The ACEI group had the best patient survival trend among the four groups. In multivariable Cox regression analyses, no differences were observed between the ACEI and ARB groups. Among young patients and patients without diabetes or heart disease, the ACEI group had the best patient survival among the four groups. However, among patients with DM or heart disease, the ARB group had the best patient survival.Conclusions Our study found that patients receiving ACEI and ARB had comparable survival. However, patients receiving ARB had better survival in the subgroups of patients with DM or heart disease, and patients receiving ACEI had better survival in the subgroup of young patients or patients without diabetes or heart disease. |
| format | Article |
| id | doaj-art-24cf2ab797a44abd84c780d214e2efe8 |
| institution | Kabale University |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-24cf2ab797a44abd84c780d214e2efe82025-01-23T04:17:48ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146110.1080/0886022X.2024.2313173Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort studySeok Hui Kang0Gui Ok Kim1Bo Yeon Kim2Eun Jung Son3Jun Young Do4Department of Internal Medicine, Division of Nephrology, College of Medicine, Yeungnam University, Daegu, Republic of KoreaHealth Insurance Review and Assessment Service, Wonju, Republic of KoreaHealth Insurance Review and Assessment Service, Wonju, Republic of KoreaHealth Insurance Review and Assessment Service, Wonju, Republic of KoreaDepartment of Internal Medicine, Division of Nephrology, College of Medicine, Yeungnam University, Daegu, Republic of KoreaBackground This study aimed to evaluate the patient survival rates based on the use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in a large cohort of patients undergoing maintenance hemodialysis (HD).Methods Data from a national HD quality assessment program were used in this retrospective study. The patients were classified into four groups based on the use of renin-angiotensin system blockers (RASBs) as follows: No group, patients without a prescription of any anti-hypertensive drugs including RASBs; Other group, patients with a prescription of anti-hypertensive drugs excluding RASBs; ACEI group, patients with a prescription of an ACEI; and ARB group, patients with a prescription of an ARB.Results The 5-year survival rates in the no, other, ACEI, and ARB groups were 68.6%, 67.8%, 70.6%, and 69.2%, respectively. The ACEI group had the best patient survival trend among the four groups. In multivariable Cox regression analyses, no differences were observed between the ACEI and ARB groups. Among young patients and patients without diabetes or heart disease, the ACEI group had the best patient survival among the four groups. However, among patients with DM or heart disease, the ARB group had the best patient survival.Conclusions Our study found that patients receiving ACEI and ARB had comparable survival. However, patients receiving ARB had better survival in the subgroups of patients with DM or heart disease, and patients receiving ACEI had better survival in the subgroup of young patients or patients without diabetes or heart disease.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2313173Hemodialysismortalityangiotensin-converting enzyme inhibitorangiotensin receptor blocker |
| spellingShingle | Seok Hui Kang Gui Ok Kim Bo Yeon Kim Eun Jung Son Jun Young Do Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study Renal Failure Hemodialysis mortality angiotensin-converting enzyme inhibitor angiotensin receptor blocker |
| title | Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study |
| title_full | Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study |
| title_fullStr | Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study |
| title_full_unstemmed | Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study |
| title_short | Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study |
| title_sort | effect of angiotensin converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis a nationwide observational cohort study |
| topic | Hemodialysis mortality angiotensin-converting enzyme inhibitor angiotensin receptor blocker |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2313173 |
| work_keys_str_mv | AT seokhuikang effectofangiotensinconvertingenzymeinhibitorsversusthatofangiotensinreceptorblockersonsurvivalinpatientsundergoinghemodialysisanationwideobservationalcohortstudy AT guiokkim effectofangiotensinconvertingenzymeinhibitorsversusthatofangiotensinreceptorblockersonsurvivalinpatientsundergoinghemodialysisanationwideobservationalcohortstudy AT boyeonkim effectofangiotensinconvertingenzymeinhibitorsversusthatofangiotensinreceptorblockersonsurvivalinpatientsundergoinghemodialysisanationwideobservationalcohortstudy AT eunjungson effectofangiotensinconvertingenzymeinhibitorsversusthatofangiotensinreceptorblockersonsurvivalinpatientsundergoinghemodialysisanationwideobservationalcohortstudy AT junyoungdo effectofangiotensinconvertingenzymeinhibitorsversusthatofangiotensinreceptorblockersonsurvivalinpatientsundergoinghemodialysisanationwideobservationalcohortstudy |